Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
ARN25068
Cat. No.:
0225LY-1102
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
ARN25068 acts as a powerful inhibitor of the DYRK1A, FYN, and GSK-3β protein kinases at sub-micromolar levels, effectively mitigating the hyperphosphorylation of tau.
Synonym:
2649882-80-2; 2-N-benzyl-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)thieno[3,2-d]pyrimidine-2,4-diamine
CAS No.:
2649882-80-2
Compound CID:
49830886
Formula:
C19H18N6S
Formula Weight:
362.45
Specification
Targets&IC50:
GSK-3β: 4.17 μM; FYN: 2.17 μM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ARN25068 can be used in signaling pathway studies to explore its role as a potent inhibitor of the MICAL1 protein.
Library Information
Target:
Microtubule; Src; GSK-3; DYRK
Receptor:
GSK-3β; Fyn; DYRK1A; tau
Pathways:
Cytoskeletal signaling; Angiogenesis; PI3K/Akt/mTOR signaling; Cell cycle/Checkpoint; Stem cell regulation; Tyrosine kinase/adaptors
Plate Number:
AOCL-15
Plate Location:
b8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 151.75 mM
